Invention Grant
- Patent Title: MCL-1 inhibitors and methods of use thereof
-
Application No.: US15790660Application Date: 2017-10-23
-
Publication No.: US10196404B2Publication Date: 2019-02-05
- Inventor: Alexander Hird , Matthew Belmonte , Wenzhan Yang , Paul Secrist , Daniel Robbins , Steven Kazmirski , Dedong Wu , Bo Peng , Jeffrey Johannes , Michelle Lamb , Qing Ye , Xiaolan Zheng
- Applicant: AstraZeneca AB
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agent Meaghan Lynn Richmond
- Main IPC: C07D497/22
- IPC: C07D497/22 ; C07D515/22
Abstract:
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
Public/Granted literature
- US20180155362A1 MCL-1 INHIBITORS AND METHODS OF USE THEREOF Public/Granted day:2018-06-07
Information query
